New study reveals potential link between GLP1 agonists and depression: Calls for urgent attention Dr. Kamal Kant Kohli24 April 2025 8:30 PM ISTA groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1...
Novo Nordisk Withdrawal to Reshape Insulin Market; Lupin's Huminsulin to Gain Spotlight Farhat Nasim24 April 2025 6:29 PM ISTMumbai: Amidst the ongoing news of conventional insulin market disruption and growing concern over potential shortages triggered by Novo...
As Ozempic, Wegovy Take Priority, Novo Nordisk Winds Down Insulin Portfolio In India Farhat Nasim22 April 2025 7:04 PM ISTNew Delhi: Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand. This...
Medical Bulletin 22/ April/ 2025 Dr. Bhumika Maikhuri22 April 2025 3:00 PM ISTHere are the top medical news for the day:Can a Handful of Almonds Help Lower Cholesterol and Blood Sugar?A new consensus study has reinforced the...
GLP1 Drugs May Pose Mental Health Risks, New Study Warns Dr. Bhumika Maikhuri22 April 2025 8:15 AM ISTA new study published in Current Neuropharmacology has raised alarms about the potential mental health risks associated with Glucagon-like Peptide-1...
GLP-1 drug shows little benefit for people with Parkinson's disease: Study Dr. Kamal Kant Kohli2 March 2025 9:30 PM ISTThe GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL...
Semaglutide shows promise in reducing cravings for alcohol, heavy drinking, finds study Dr. Kamal Kant Kohli14 Feb 2025 8:15 AM ISTThe blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol...
FDA approves Semaglutide for renal protection among diabetes patients with CKD Dr. Kamal Kant Kohli30 Jan 2025 9:00 AM ISTNovo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk of worsening kidney...
Novo Nordisk Ozempic get USFDA nod for reduction of kidney disease worsening risk, cardiovascular death in adults with type 2 diabetes, chronic kidney disease Ruchika Sharma29 Jan 2025 1:30 PM ISTPlainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease...
Which are High-impact clinical trials that may generate promising results for improving kidney health? Dr Kartikeya Kohli1 Nov 2024 8:00 PM ISTThe results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney...
Semaglutide may reduce risk of Alzheimer's disease in diabetes patients, suggests study Dr. Kamal Kant Kohli25 Oct 2024 8:00 PM ISTResearchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of...
Glucagon-like peptide-1 receptor agonists may be new treatment for opioid and alcohol use disorder, finds study Dr. Kamal Kant Kohli19 Oct 2024 9:00 AM ISTOzempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity,...
